Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
August 17, 2022 08:00 ET
|
Magenta Therapeutics
CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of...
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
August 04, 2022 08:00 ET
|
Magenta Therapeutics
– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions, rapid drug clearance and a favorable tolerability...
Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference
August 02, 2022 08:00 ET
|
Magenta Therapeutics
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of...